Watch Out: What Personalized Depression Treatment Is Taking Over And How To Stop It > 자유게시판

Personalized Depression Treatment

Traditional therapies and medications don't work for a majority of patients suffering from depression. Personalized treatment could be the answer.

Cue is an intervention platform that converts sensor data collected from smartphones into personalised micro-interventions for improving mental health. We examined the most effective-fitting personalized ML models to each subject using Shapley values, in order to understand their features and predictors. The results revealed distinct characteristics that deterministically changed mood over time.

Predictors of Mood

Depression is a major cause of mental illness around the world.1 Yet the majority of people affected receive treatment. To improve outcomes, healthcare professionals must be able to identify and treat patients who have the highest likelihood of responding to particular treatments.

Personalized depression treatment is one method to achieve this. Researchers at the University of Illinois Chicago are developing new methods to predict which patients will gain the most from certain treatments. They make use of sensors for mobile phones and a voice assistant incorporating artificial intelligence, and other digital tools. With two grants awarded totaling over $10 million, they will employ these tools to identify biological and behavioral predictors of responses to antidepressant medications as well as psychotherapy.

The majority of research to the present has been focused on clinical and sociodemographic characteristics. These include demographics such as gender, age and education, and clinical characteristics like severity of symptom and comorbidities as well as biological markers.

While many of these variables can be predicted from information available in medical records, only a few studies have used longitudinal data to explore the factors that influence mood in people. A few studies also consider the fact that moods can vary significantly between individuals. Therefore, it is critical to create methods that allow the recognition of different mood predictors for each person and treatments effects.

The team's new approach uses daily, in-person evaluations of mood and lifestyle variables using a smartphone app called AWARE, a cognitive evaluation with the BiAffect app and electroencephalography -- an imaging technique that monitors brain activity. This enables the team to create algorithms that can detect distinct patterns of behavior and emotions that differ between individuals.

The team also created a machine-learning algorithm that can identify dynamic predictors of the mood of each person's depression. The algorithm combines the individual differences to create a unique "digital genotype" for each participant.

This digital phenotype was correlated with CAT DI scores, a psychometrically validated scale for assessing severity of symptom. The correlation was weak, however (Pearson r = 0,08; P-value adjusted by BH 3.55 10 03) and varied greatly among individuals.

Predictors of symptoms

Depression is a leading reason for disability across the world, but it is often untreated and misdiagnosed. Depression disorders are usually not treated due to the stigma that surrounds them and the absence of effective treatments.

To aid in the development of a personalized treatment plan, identifying patterns that can predict symptoms is essential. However, current prediction methods depend on the clinical interview which is not reliable and only detects a limited number of features associated with depression.2

Machine learning can enhance the accuracy of diagnosis and treatment for depression by combining continuous digital behavioral phenotypes collected from smartphone sensors with a valid mental health tracker online (the Computerized Adaptive Testing Depression Inventory CAT-DI). Digital phenotypes are able to are able to capture a variety of unique actions and behaviors that are difficult to record through interviews, and allow for high-resolution, continuous measurements.

The study included University of California Los Angeles (UCLA) students experiencing mild to severe depression symptoms. participating in the Screening and Treatment for Anxiety and Depression (STAND) program29 developed under the UCLA Depression Grand Challenge. Participants were directed to online support or in-person clinical treatment in accordance with their severity of depression treatment no medication. Participants with a CAT-DI score of 35 or 65 were assigned online support by a coach and those with a score 75 patients were referred to in-person clinics for psychotherapy.

At the beginning of the interview, participants were asked the answers to a series of questions concerning their personal demographics and psychosocial features. The questions included age, sex, and education, financial status, marital status, whether they were divorced or not, current suicidal thoughts, intentions or attempts, and the frequency with which they consumed alcohol. Participants also rated their level of depression symptom severity on a scale of 0-100 using the CAT-DI. The CAT-DI assessment was carried out every two weeks for those who received online support and weekly for those who received in-person support.

Predictors of the Reaction to Treatment

Research is focused on individualized treatment for depression. Many studies are focused on identifying predictors, which will help doctors determine the most effective medications to treat each patient. In particular, pharmacogenetics identifies genetic variants that determine how the body metabolizes antidepressants. This lets doctors choose the medications that are most likely to work for each patient, while minimizing the amount of time and effort required for trial-and error treatments and avoiding any side consequences.

Another approach that is promising is to build models of prediction using a variety of data sources, including clinical information and neural imaging data. These models can be used to determine which variables are most likely to predict a specific outcome, such as whether a drug will improve mood or symptoms. These models can be used to determine the patient's response to home treatment for depression that is already in place which allows doctors to maximize the effectiveness of the treatment currently being administered.

A new generation uses machine learning techniques like the supervised and classification algorithms such as regularized logistic regression, and tree-based techniques to combine the effects of several variables and improve predictive accuracy. These models have been shown to be useful in predicting treatment outcomes, such as response to antidepressants. These techniques are becoming increasingly popular in psychiatry and will likely be the norm in future treatment.

In addition to ML-based prediction models research into the underlying mechanisms of depression is continuing. Recent findings suggest that depression is linked to dysfunctions in specific neural networks. This suggests that an individualized treatment for depression will depend on targeted therapies that restore normal function to these circuits.

One way to do this is by using internet-based programs that offer a more individualized and personalized experience for patients. For instance, one study discovered that a web-based treatment was more effective than standard care in reducing symptoms and ensuring the best quality of life for those suffering from MDD. A randomized controlled study of a customized treatment for depression Treatment Centers near me revealed that a significant percentage of patients saw improvement over time and fewer side consequences.

Predictors of Side Effects

A major obstacle in individualized depression treatment is predicting the antidepressant medications that will have the least amount of side effects or none at all. Many patients take a trial-and-error approach, using several medications prescribed until they find one that is effective and tolerable. Pharmacogenetics provides a novel and exciting way to select antidepressant medicines that are more effective and specific.

There are several variables that can be used to determine the antidepressant that should be prescribed, including genetic variations, patient phenotypes such as gender or ethnicity, and co-morbidities. To determine the most reliable and accurate predictors for a particular treatment, randomized controlled trials with larger samples will be required. This is because the identifying of interactions or moderators could be more difficult in trials that only focus on a single instance of treatment per person, rather than multiple episodes of treatment over time.

Furthermore, the prediction of a patient's response to a particular medication will also likely need to incorporate information regarding comorbidities and symptom profiles, and the patient's prior subjective experiences with the effectiveness and tolerability of the medication. Currently, only some easily measurable sociodemographic and clinical variables appear to be reliably associated with the response to MDD factors, including age, gender, race/ethnicity and SES, BMI and the presence of alexithymia, and the severity of depressive symptoms.

Many issues remain to be resolved in the application of pharmacogenetics for depression treatment. First, a clear understanding of the genetic mechanisms is required, as is a clear definition of what is a reliable predictor of treatment response. Additionally, ethical issues like privacy and the ethical use of personal genetic information must be carefully considered. In the long term the use of pharmacogenetics could offer a chance to lessen the stigma associated with mental health treatment and to improve treatment outcomes for those struggling with depression. But, like any approach to psychiatry careful consideration and planning is essential. For now, it is best to offer patients an array of depression treatment without drugs medications that are effective and urge them to talk openly with their physicians.